FDA Brief

Warning letters Devices

FDA warning letter to

Wickimed Medical Equipment Manufacturing Co., Ltd.

High riskIssued Jan 7, 2022Posted Mar 8, 2022Center for Devices and Radiological Health

FDA warned China-based Wickimed over quality system failures in making sterile single-use electrodes, including unsterilized product labeled sterile.

What happened

FDA inspected Wickimed's Huizhou, China facility from September 6 to September 14, 2021 and found the company was not following the Quality System regulation (the FDA rule for how medical devices must be made). Investigators found no sterilization validation data, no design control records, and multiple pallets of finished devices labeled "Sterile" that had never been sterilized at the off-site ethylene oxide (EtO) sterilization facility. The company's written responses were mostly in a foreign language with limited English translation, so FDA could not fully assess them.

What FDA found

  1. The company had no procedure to make sure it receives complaints from the US distributor selling its private-label devices, and no agreement requiring the distributor to pass complaints along.

    21 CFR 820.198(a)
  2. The company could not provide validation data or records showing its sterilization process reliably works.

    21 CFR 820.75(a)
  3. The company lacked proper design control procedures and could not produce design history file or 510(k) documents for the electrodes.

    21 CFR 820.30(a)
  4. Finished devices that had not been sterilized were labeled "Sterile" on multiple pallets intended for the US market, with no procedure to mark them non-sterile.

    21 CFR 820.86
  5. Controlled documents, including internal audit records and sterilization and sterility test records, were found outside their designated locations.

    21 CFR 820.40
  6. The company's adverse-event procedure was not written as a Medical Device Reporting procedure meeting FDA's reporting requirements.

    21 CFR 803.17

What FDA wants

FDA asks the company to reply in writing within 15 business days describing the specific corrections and corrective actions taken, how it will prevent repeat violations, a timetable for anything not yet finished, and full English translations of all documents. FDA also says the devices will be held at the US border (detention without physical examination) until the violations are fixed.

Who should pay attention

  • US brands and distributors that private-label these electrodes
  • hospitals and clinics that buy sterile single-use electrodes
  • contract manufacturers and sterilization providers serving US device firms

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Avertix Medical, Inc.

    FDA warns Avertix Medical over Guardian implantable cardiac event detector quality violations and late injury reports.

    High risk
  2. BRS Analytical Services, LLC

    BRS Analytical Services, LLC made sterile OTC drugs in an unsuitable aseptic facility and recalled them over sterility assurance.

    High risk
  3. LeMaitre Vascular, Inc.

    LeMaitre Vascular's Artegraft graft plant in New Jersey drew an FDA warning letter for water, sterilization and recall-reporting failures.

    High risk
  4. Wuxi Medical Instrument Factory Co., Ltd.

    FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.

    High risk